scholarly journals Estrogen Receptor-mediated Activation of the Serum Response Element in MCF-7 Cells through MAPK-dependent Phosphorylation of Elk-1

2001 ◽  
Vol 276 (15) ◽  
pp. 11590-11598 ◽  
Author(s):  
Renqin Duan ◽  
Wen Xie ◽  
Robert C. Burghardt ◽  
Stephen Safe

17β-Estradiol (E2) induces c-fosprotooncogene expression in MCF-7 human breast cancer cells, and deletion analysis of the c-fospromoter showed that the serum response element (SRE) at −325 to −296 was E2-responsive. The mechanism of ligand-activated estrogen receptor α (ERα)-dependent activation of gene expression through the SRE was determined by mutational analysis of the promoter, analysis of mitogen-activated protein kinase (MAPK) pathway activation by E2, and transforming growth factor α (TGF-α) as a positive control. In addition, ERα-negative MDA-MB-231 breast cancer and Chinese hamster ovary cells were used as reference cell lines. The results showed that transcriptional activation of the SRE by E2 was due to ERα activation of the MAPK pathway and increased binding of the serum response factor and Elk-1 to the SRE. Subsequent studies with dominant negative Elk-1, wild type, and variant GAL4-Elk-1 fusion proteins confirmed that phosphorylation of Elk-1 at serines 383 and 389 in the C-terminal region of Elk-1 is an important downstream target associated with activation of an SRE by E2. Both E2 (ERα-dependent) and growth factors (ERα-independent) activated the SRE in breast cancer cells via the Ras/MAPK pathway; however, in ER-negative CHO cells that do not express a receptor for TGF-α, only hormone-induced activation was observed in cells transfected with ERα.

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Mariana A. Callero ◽  
Andrea I. Loaiza-Pérez

Many estrogen-receptor- (ER-) expressing breast cancers become refractory to ER-based therapies. New antitumor drugs like aminoflavone (AF) and benzothiazoles (Bzs) have been developed and have exquisite antitumor activity in ER+MCF-7 and T47D cells and in a MCF-7 nude mouse model. ER(−) breast cancer cells like MDA-MB-231 are less susceptible. We previously found in MCF-7 cells that these drugs activate the aryl hydrocarbon receptor (AhR) via translocation to the nucleus, induction of AhR-specific DNA binding activity, and expression of CYP1A1, whose transcription is controlled by the AhR-ARNT transcription factor. CYP1A1 metabolizes AF and Bz to a species which directly or after further metabolism damages DNA. In contrast an AhR-deficient variant of MCF-7 or cells with predominantly nuclear AhR expression, such as MDA-MB 231, are resistant. Thus, these drugs, unlike other neoplastic agents, require AhR-mediated signaling to cause DNA damage. This is a new treatment strategy for breast cancers with intact AhR signaling.


Endocrinology ◽  
1984 ◽  
Vol 114 (2) ◽  
pp. 629-637 ◽  
Author(s):  
RICHARD L. ECKERT ◽  
ALAKA MULLICK ◽  
ELLEN A. RORKE ◽  
BENITA S. KATZENELLENBOGEN

Sign in / Sign up

Export Citation Format

Share Document